Resource Center

Publications

Publications and clinical research supporting AIQ Solutions technology platform

DESCRIPTION OF TECHNOLOGY

  1. Vanderhoek M, Juckett MB, Perlman S, et al.  Early assessment of treatment response in patients with AML using [18F]FLT PET imaging. Leuk Res. 2011;35(3):310–316.
  2. Yip S, Perk T, Jeraj R. Development and evaluation of an articulated registration algorithm for human skeleton registration. Phys Med Biol. 2014;59(6):1485-1499.
  3. Yip S, Jeraj R. Use of articulated registration for response assessment of individual metastatic bone lesions. Phys Med Biol. 2014;59(6):1501-1514.
  4. Simoncic U, Perlman S, Liu G, et al.  Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer. 2015;13(1):e7-17.
  5. Muzahir S, Jeraj R, Liu G, et al.  Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with 18F-NaF PET/CT in castrate resistant prostate cancer patients. Am J Nucl Med Mol Imaging. 2015;5(2):162-168.
  6. Harmon S, Bergvall E, Mena E, et al.  A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer. J Nucl Med. 2018;59(11):1665-1671.
  7. Perk T, Chen S, Harmon S, et al.  A statistically optimized regional thresholding method (SORT) for bone lesion detection in 18F-NaF PET/CT imaging. Phys Med Biol. 2018;63(22).
  8. Perk T, Bradshaw T, Chen S, et al.  Automated classification of benign and malignant lesions in 18F-NaF PET/CT images using machine learning. Phys Med Biol. 2018;63(22).

TECHNOLOGY ROBUSTNESS AND REPEATABILITY

  1. Lin C, Bradshaw T, Perk T, et al.  Repeatability of quantitative 18F-NaF PET: a multicenter study. J Nucl Med.2016;57(12):1872-1879.

CORRELATION BETWEEN ANALYSIS AND CLINICAL OUTCOMES

  1. Harmon SA, Perk T, Lin C, et al.  Quantitative assessment of early [18F]sodium fluoride positron emission tomography/computed tomography response to treatment in men with metastatic prostate cancer to bone. J Clin Oncol.2017;35(24):2829-2837.
  2. Scarpelli M, Zahm C, Perlman S, et al.  FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. J Immunother Cancer. 2018;7(23).
  3. Kyriakopoulos CE, Heath EI, Ferrari A, et al. Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. J. Clin Oncol. 2020;38(31):3662-3671

BIOLOGICAL VALIDATION

  1. Roth A, Tomlins SA, Tuite M, et al.  Targeting differential response using molecular guided biopsies in bone-metastatic prostate cancer. J Clin Oncol 2019;37(suppl; abstr e16516).

VALUABLE INTELLIGENCE AT THE TIME OF PATIENT MANAGEMENT DECISION MAKING

  1. Kyriakopoulos CE, Heath EI, Ferrari A, et al.  Interlesional Response Assessment With 18F-SodiumFluoride (18F-NaF) PET/CT in Men With Chemotherapy-Naive Bone Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide. Poster presented at 2019 American Society for Clinical Oncology Annual Meeting; June, 2019; Chicago, IL.
  2. McNeel DG, Eickhoff JC, Johnson LE, et al.  Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer. J Clin Oncol. 2019;37(36):3507-3517.
  3. Ongoing clinical trial: Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: the CHAARTED2 Trial:  A trial of the ECOG-ACRIN Cancer Research Group (EA8153).

ECONOMIC CONSIDERATIONS

  1. CMS Office of Enterprise Data & Analytics (OEDA). Medicare Part B Drug SpendingDashboard
  2. Mariotto AB,Enewold L, Zhao J, et al. Medical Care Costs Associated with CancerSurvivorship in the United States. Cancer Epidem Biomar.2020;29(7):1304-12.
Resource Center

Learn more about AIQ Solutions TEchnology

Discover the publications and clinical research supporting AIQ Solutions technology platform
Explore publications
View posters that AIQ has presented or contributed to at different seminars and conferences
Review our posters
AIQ has multiple white papers which highlight our unique technology, heterogeneity, and other subjects
See white papers
See how AIQ Solutions is able to assist in understanding treatment in different applications
Review notes
See how AIQ Solutions is able to assist in understanding treatment in different applications
Review reports
Get insights from our team and keep up-to-date on interesting topics relating to AIQ technology
Read the blogs
Learn more about treatment response challenges facing clinical studies and patient management
Explore our videos
Learn how TRAQinform IQ™ technology has become an essential component of clinical studies.
See our webinars
Review policy documents showing how AIQ is complying with applicable regulations.
Review policies